EUVIMEDEUVIMED entdecken
Crossref

Synergistic Induction of Ferroptosis by GPX4 Inhibitor and GSH‐Depleted Nanoparticles Effectively Reverses Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma PDX Model

Chen-Song Huang, Chunlei Dai, Qi Liu, Si-Yun Chen, Ya-Hao Guo, Jie-Qin Wang, An-Da Zheng, Xi-Tai Huang, Jun Wu iD, Xiao-Yu Yin

Advanced Healthcare Materials · 2026-03 · 15 (11)

DOI: 10.1002/adhm.202503694 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 26.12.2025. Verfasst von Chen-Song Huang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pancreato-Biliary Surgery, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Ferroptosis, Deoxycytidine, Carcinoma, Pancreatic Ductal, Nanoparticles. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Guangdong Basic and Applied Basic Research Foundation, Affiliated Qingyuan Hospital of Guangzhou Medical University Open Project Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ferroptosis has emerged as a critical mechanism in overcoming drug resistance in various tumors; however, its role in gemcitabine‐resistant pancreatic ductal adenocarcinoma (PDAC) has not been thoroughly explored. Additionally, the effectiveness of ferroptosis in many cancer therapies has been limited. In our study, we found that GPX4 is upregulated in gemcitabine‐resistant (GR) PDAC patient tissues and cell lines. Notably, inhibiting GPX4 can reverse gemcitabine resistance in PDAC through the induction of ferroptosis, highlighting it as a potential therapeutic target. To address this, we developed a novel nanomedicine, GSH‐depleted and ferroptosis‐induced (FiN), designed to encapsulate and deliver the GPX4 inhibitor RSL3, resulting in a dual ferroptosis‐induced nanomedicine (DFiN). In a PDAC patient‐derived xenograft (PDX) mouse model exhibiting gemcitabine resistance, DFiN demonstrated significant accumulation in GR PDAC tumors, leading to a reduction in intracellular GSH levels and inhibition of GPX4. This dual action promoted lipid peroxidation and synergistically induced ferroptosis, effectively reversing gemcitabine resistance. Both in vitro and in vivo experiments confirmed that DFiN is effective in overcoming gemcitabine resistance in GR PDAC cells and PDX tumors, with minimal toxicity observed. This study presents a promising strategy for addressing drug resistance in cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisDeoxycytidineCarcinoma, Pancreatic DuctalNanoparticlesDrug Resistance, NeoplasmGlutathionePancreatic NeoplasmsPhospholipid Hydroperoxide Glutathione PeroxidaseGemcitabineAnimalsHumansMiceCell Line, TumorXenograft Model Antitumor AssaysDrug SynergismCarbolines

Stichwörter der Autor:innen

GSH‐depleted nanoparticlesferroptosisgemcitabine resistancepancreatic ductal adenocarcinoma

Substanzen

DeoxycytidineGemcitabineGlutathionePhospholipid Hydroperoxide Glutathione PeroxidaseRSL3 compoundCarbolines

Autor:innen und Institutionen

  • Department of Pancreato-Biliary Surgery, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
  • Department of Hematologic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Bioscience and Biomedical Engineering Thrust, The Hong Kong University of Science and Technology (Guangzhou), Nansha, Guangzhou, China.
  • Department of Liver Surgery Sun Yat-sen University Cancer Center Guangzhou, Guangdong, P. R. China.
  • Key Laboratory of Stem Cells and Tissue Engineering, Ministry of Education, Sun Yat-sen University, Guangzhou, China.
  • Department of Pediatric Surgery, Guangzhou Women and Children's Medical Center, Guangdong Provincial Clinical Research Center for Child Health, Guangzhou Medical University, Guangzhou, China.

ORCID-Profile: Jun Wu

Förderung

  • National Natural Science Foundation of China
  • Guangdong Basic and Applied Basic Research Foundation
  • Affiliated Qingyuan Hospital of Guangzhou Medical University Open Project Fund
  • Guangzhou Science Technology Program City-University Joint Funding Project
  • Guangzhou Science and Technology Program Project
  • Basic and Applied Basic Research Foundation of Guangdong Province

Zitieren

APA

Huang, C. S., Dai, C., Liu, Q., Chen, S. Y., Guo, Y. H., Wang, J. Q., Zheng, A. D., Huang, X. T., Wu, J., & Yin, X. Y. (2026). Synergistic Induction of Ferroptosis by GPX4 Inhibitor and GSH‐Depleted Nanoparticles Effectively Reverses Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma PDX Model. Advanced Healthcare Materials, 15(11). https://doi.org/10.1002/adhm.202503694

Vancouver

Huang CS, Dai C, Liu Q, Chen SY, Guo YH, Wang JQ, et al. Synergistic Induction of Ferroptosis by GPX4 Inhibitor and GSH‐Depleted Nanoparticles Effectively Reverses Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma PDX Model. Advanced Healthcare Materials. 2026;15(11). doi:10.1002/adhm.202503694

BibTeX
@article{Huang2026,
  author = {Huang, Chen-Song and Dai, Chunlei and Liu, Qi and Chen, Si-Yun and Guo, Ya-Hao and Wang, Jie-Qin and Zheng, An-Da and Huang, Xi-Tai and Wu, Jun and Yin, Xiao-Yu},
  title = {Synergistic Induction of Ferroptosis by GPX4 Inhibitor and GSH‐Depleted Nanoparticles Effectively Reverses Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma PDX Model},
  journal = {Advanced Healthcare Materials},
  year = {2026},
  volume = {15},
  number = {11},
  doi = {10.1002/adhm.202503694}
}
Kostenlos starten →